Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Lam, Yu Ming Paul ^a,b   McBride, Kristin L ^a,b   Amin, Janaki ^a,b   Cordery, Damien V ^a,b   Kelleher, Anthony D ^a,b   Cooper, David A ^a,b   Koelsch, Kersten K ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FOSAMPRENAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; TENOFOVIR; VIRUS DNA; 2 PYRROLIDONE DERIVATIVE; ANTIVIRUS AGENT; DNA; PRIMER DNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONG TERMINAL REPEAT; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD; COHORT ANALYSIS; CYTOLOGY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; METHODOLOGY; MIDDLE AGED; MONONUCLEAR CELL;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DNA; DNA PRIMERS; DNA, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PYRROLIDINONES; REAL-TIME POLYMERASE CHAIN REACTION; TERMINAL REPEAT SEQUENCES; VIRAL LOAD;

EID: 84857718947     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031990     Document Type: Article

References (33)

1. Chun TW, Engel D, Berrey MM, Shea T, Corey L, et al. (1998) Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America 95: 8869-8873.
2. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
3. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295.
4. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
5. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, et al. (2005) HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 115: 3250-3255.
6. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, et al. (2008) Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. Journal of Infectious Diseases 197: 714-720.
7. Murray JM, Emery S, Kelleher AD, Law M, Chen J, et al. (2007) Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. Aids 21: 2315-2321.
8. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, et al. (2008) Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 359: 339-354.
9. Buzon MJ, Codoner FM, Frost SD, Pou C, Puertas MC, et al. (2011) Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART. PLoS Pathog 7: e1002314.
10. Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, et al. (2004) A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proceedings of the National Academy of Sciences of the United States of America 101: 11233-11238.
11. Goffinet C, Allespach I, Oberbremer L, Golden PL, Foster SA, et al. (2009) Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo. J Virol 83: 7706-7717.
12. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, et al. (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nature Medicine 16: 460-465.
13. Boyum A, (1968) Separation of leukocytes from blood and bone marrow. Introduction. Scand J Clin Lab Invest Suppl 97: 7.
14. Suzuki K, Shijuuku T, Fukamachi T, Zaunders J, Guillemin G, et al. (2005) Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region. J RNAi Gene Silencing 1: 66-78.
15. Cordery DV, Hesse K, Amin J, Cooper DA, (2010) Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antiviral Therapy 15: 1035-1038.
16. Delaugerre C, Charreau I, Braun J, Nere ML, de Castro N, et al. (2010) Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen. Aids 24: 2391-2395.
17. Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, et al. (2010) Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. Aids 24: 2451-2460.
18. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, et al. (2010) Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. Journal of Infectious Diseases 202: 1553-1561.
19. Chun TW, Justement JS, Murray D, Hallahan CW, Maenza J, et al. (2010) Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. Aids 24: 2803-2808.
20. Guadalupe M, Sankaran S, George MD, Reay E, Verhoeven D, et al. (2006) Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection. J Virol 80: 8236-8247.
21. Poles MA, Boscardin WJ, Elliott J, Taing P, Fuerst MM, et al. (2006) Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr 43: 65-68.
22. Ruiz L, van Lunzen J, Arno A, Stellbrink HJ, Schneider C, et al. (1999) Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. Aids 13: F1-8.
23. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, et al. (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nature Medicine 14: 762-766.
24. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW, et al. (2004) Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. Journal of Infectious Diseases 189: 1452-1465.
25. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, et al. (2008) HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proceedings of the National Academy of Sciences of the United States of America 105: 16725-16730.
26. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, et al. (2009) Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 106: 9403-9408.
27. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, et al. (2010) Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clinical Infectious Diseases 50: 912-919.
28. Grant PM, Palmer S, Bendavid E, Talbot A, Slamowitz DC, et al. (2009) Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. J Clin Virol 46: 305-308.
29. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, et al. (2010) The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 7.
30. Svarovskaia ES, Barr R, Zhang X, Pais GC, Marchand C, et al. (2004) Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J Virol 78: 3210-3222.
31. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, et al. (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287: 646-650.
32. Zhu W, Jiao Y, Lei R, Hua W, Wang R, et al. (2011) Rapid Turnover of 2-LTR HIV-1 DNA during Early Stage of Highly Active Antiretroviral Therapy. PLoS ONE [Electronic Resource] 6: e21081.
33. Koelsch KK, Boesecke C, McBride K, Gelgor L, Danta M, et al. (2011) HIV-1 RNA and DNA decay characteristics during treatment with raltegravir in antiretroviral naive patients Aids In Press.